A Randomized, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Ulipristal Acetate for the Intermittent Treatment of Abnormal Uterine Bleeding Associated With Leiomyomas

Trial Profile

A Randomized, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Ulipristal Acetate for the Intermittent Treatment of Abnormal Uterine Bleeding Associated With Leiomyomas

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Jul 2017

At a glance

  • Drugs Ulipristal (Primary)
  • Indications Uterine haemorrhage; Uterine leiomyoma
  • Focus Registrational; Therapeutic Use
  • Acronyms Venus II
  • Sponsors Actavis; Allergan
  • Most Recent Events

    • 28 Jun 2017 Status changed from active, no longer recruiting to completed.
    • 17 Jan 2017 Results published in the Allergan Media Release.
    • 06 Dec 2016 Planned End Date changed from 1 Nov 2016 to 1 Jan 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top